** Shares of biotech firm Aligos Therapeutics ALGS.O rise 3.8% to $27 premarket
** ALGS says it is raising $105 million in a private placement financing
** Co is selling ~2.1 million shares of common stock along with warrants to purchase up to ~2 million additional shares at a combined purchase price of $26.0825/shr
** Combined purchase price is at a 0.2% premium to the stock's last close
** Co says the funding will be used to start a mid-stage trial for ALG-000184, a treatment for chronic hepatitis B virus infection
** Co says the funding will extend its cash runway into the H2 of 2026
** Co has 3.6 million outstanding shares, with market cap of $93.4 million - LSEG data
** Jefferies and Piper Sandler are acting as placement agents
** ALGS shares more than doubled in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。